These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27313108)

  • 1. Molecular epidemiology and antimicrobial susceptibility of AmpC- and/or extended-spectrum (ESBL) ß-lactamaseproducing Proteus spp. clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina.
    Uzunović S; Ibrahimagić A; Hodžić D; Bedenić B
    Med Glas (Zenica); 2016 Aug; 13(2):103-12. PubMed ID: 27313108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic resistance in Enterobacter cloacae strains with derepressed/partly derepressed/inducible AmpC and extendedspectrum beta-lactamases in Zenica-Doboj Canton, Bosnia and Herzegovina.
    Uzunović S; Ibrahimagić A; Bedenić B
    Med Glas (Zenica); 2018 Feb; 15(1):37-45. PubMed ID: 29214986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings.
    Ibrahimagić A; Bedenić B; Kamberović F; Uzunović S
    J Infect Chemother; 2015 May; 21(5):363-9. PubMed ID: 25638292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methicillin-resistant S. aureus (MRSA), extended-spectrum (ESBL)- and plasmid-mediated AmpC ß-lactamase -producing Gram-negative bacteria associated with skin and soft tissue infections in hospital and community settings.
    Uzunović S; Bedenić B; Budimir A; Ibrahimagić A; Kamberović F; Fiolić Z; Rijnders MI; Stobberingh EE
    Med Glas (Zenica); 2015 Aug; 12(2):157-68. PubMed ID: 26276654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Investigation of beta-lactamase genes and clonal relationship among the extended-spectrum beta-lactamase producing nosocomial Escherichia coli isolates].
    Görgeç S; Kuzucu Ç; Otlu B; Yetkin F; Ersoy Y
    Mikrobiyol Bul; 2015 Jan; 49(1):15-25. PubMed ID: 25706727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and characterisation of extended-spectrum and plasmid-mediated AmpC β-lactamase produced by
    Fetahagić M; Ibrahimagić A; Uzunović S; Beader N; Elveđi-Gašparović V; Luxner J; Gladan M; Bedenić B
    Arh Hig Rada Toksikol; 2021 Dec; 72(4):305-314. PubMed ID: 34985844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
    Khan MK; Thukral SS; Gaind R
    Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia.
    Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
    Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M
    J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergency (clonal spread) of methicillin-resistant Staphylococcus aureus (MRSA), extended spectrum (ESBL)--and AmpC beta-lactamase-producing Gram-negative bacteria infections at Pediatric Department, Bosnia and Herzegovina.
    Uzunović S; Bedenić B; Budimir A; Kamberović F; Ibrahimagić A; Delić-Bikić S; Sivec S; Meštrović T; Varda Brkić D; Rijnders MI; Stobberingh EE
    Wien Klin Wochenschr; 2014 Dec; 126(23-24):747-56. PubMed ID: 25193483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].
    Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ
    Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
    Taneja N; Rao P; Arora J; Dogra A
    Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of TEM, SHV and CTX-M β Lactamases in Clinical Isolates of Proteus Species in a Tertiary Care Center.
    Caubey M; Suchitra M S
    Infect Disord Drug Targets; 2018; 18(1):68-71. PubMed ID: 28443500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended double disc synergy testing reveals a low prevalence of extended-spectrum beta-lactamases in Enterobacter spp. in Vienna, Austria.
    Apfalter P; Assadian O; Daxböck F; Hirschl AM; Rotter ML; Makristathis A
    J Antimicrob Chemother; 2007 May; 59(5):854-9. PubMed ID: 17347178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
    Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
    J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of extended spectrum beta lactamase and molecular detection of blaTEM, blaSHV and blaCTX-M genotypes among Gram negative bacilli isolates from pediatric patient population in Gaza strip.
    El Aila NA; Al Laham NA; Ayesh BM
    BMC Infect Dis; 2023 Feb; 23(1):99. PubMed ID: 36803466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.